Biochemical and Biophysical Research Communications 444 (2014) 332–337

Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy

Christudas Morais [a], David M. Small [a], David A. Vesey [a,b], Jennifer Martin [c], David W. Johnson [a,b,c], Glenda C. Gobe [a,*]

[a] Centre for Kidney Disease Research, School of Medicine, The University of Queensland at Translational Research Institute, Brisbane, Queensland 4102, Australia
[b] Department of Renal Medicine, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia
[c] School of Medicine, The University of Queensland, Brisbane, Queensland 4102, Australia

ARTICLE INFO

Article history:
Received 20 December 2013
Available online 22 January 2014

Keywords:
Erythropoietin
Fibronectin
Hypertrophy
Isoproterenol
Transforming growth factor beta

ABSTRACT

The use of recombinant human erythropoietin (rhEPO) to promote repair and minimize cardiac hypertrophy after myocardial infarction has had disappointing outcomes in clinical trials. We hypothesized that the beneficial non-hematopoietic effects of rhEPO against cardiac hypertrophy could be offset by the molecular changes initiated by rhEPO itself, leading to rhEPO resistance or maladaptive hypertrophy. This hypothesis was investigated using an isoproterenol-induced model of myocardial infarct and cardiac remodelling with emphasis on hypertrophy. In h9c2 cardiomyocytes, rhEPO decreased isoproterenol-induced hypertrophy, and the expression of the pro-fibrotic factors fibronectin, alpha smooth muscle actin and transforming growth factor beta-1 (TGF-β1). In contrast, by itself, rhEPO increased the expression of fibronectin and TGF-β1. Exogenous TGF-β1 induced a significant increase in hypertrophy, which was further potentiated by rhEPO. Exogenous fibronectin not only induced hypertrophy of cardiomyocytes, but also conferred resistance to rhEPO treatment. Based on these findings we propose that the outcome of rhEPO treatment for myocardial infarction is determined by the baseline concentrations of fibronectin and TGF-β1. If endogenous fibronectin or TGF-β levels are above a certain threshold, they could cause resistance to rhEPO therapy and enhancement of cardiac hypertrophy, respectively, leading to maladaptive hypertrophy.

1. Introduction

Chronic heart failure (CHF) is the leading cause of morbidity and mortality in the Western world [1]. CHF can be the direct result of cardiovascular disease (CVD) such as myocardial infarction, hypertension and anemia, or the indirect result of distant organ malfunction, for example, chronic kidney disease. Irrespective of the primary etiology, to compensate for the pressure and volume overload imposed by CVD, the heart undergoes adaptive remodelling and becomes hypertrophic [2]. Although the initial hypertrophy is an adaptive mechanism of the heart to compensate for the stress induced by CVD, sustained hypertrophy leads to maladaptive hypertrophy and eventual heart failure [2,3]. It is now well-established that cardiac hypertrophy is an independent risk factor for nearly all forms of heart failure and that prevention of hypertrophy is an important therapeutic target to prevent heart failure [2,3].

One common characteristic of CHF, irrespective of the aetiology, is anemia. Chronic untreated anemia is an independent risk factor for the development of cardiac hypertrophy and subsequent CHF [4]. Recombinant human erythropoietin (rhEPO) has been successfully used to treat patients with chronic anemia. The biological effects of rhEPO are mediated through interactions with its receptor, EPOR. Although the amelioration of anemia by rhEPO is largely attributed to its hematopoietic effects, for example, normalization of hemoglobin and hematocrit levels [5,6], one remarkable finding is that EPO also improves cardiac hypertrophy in anemic patients, irrespective of the primary etiology of hypertrophy. These observations suggested a non-hematopoietic role for EPO beyond the correction of anemia [6]. This notion was strengthened by the identification of EPOR in many non-hematopoietic cells including cardiomyoblasts and endothelial cells [7,8].

Consequently, the non-hematopoietic effects of EPO have been extensively investigated, and animal studies have consistently concluded that EPO offers protection against cardiac hypertrophy and myocardial infarction in various models of CVD [9–11]. However, the results of clinical trials have been equivocal. In particular, the

* Corresponding author. Address: Centre for Kidney Disease Research, School of Medicine University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane 4102, Australia. Fax: +61 7 344 37779.
E-mail addresses: c.morais@uq.edu.au (C. Morais), d.small@uq.edu.au (D.M. Small), david.vesey@health.qld.gov.au (D.A. Vesey), j.martin4@uq.edu.au (J. Martin), David_Johnson@health.qld.gov.au (D.W. Johnson), g.gobe@uq.edu.au (G.C. Gobe).

0006-291X/$ - see front matter © 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bbrc.2014.01.047

phase II Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial did not demonstrate any reduction in infarct size [12]. Furthermore, in a subset of patients, there was an increase in infarct size and worse outcome in response to EPO [12]. These findings prompted an editorial in JAMA questioning the efficacy of EPO for myocardial infarction and cautioning further clinical trials [13].

Although many factors including study design, EPO dosage, time and duration of intervention have been identified as major factors, the possible molecular mechanisms behind discrepancies between animal studies and human clinical trials have not been fully explored. We hypothesize that the beneficial non-hematopoietic effects of rhEPO against cardiac hypertrophy could be offset by the molecular changes initiated by rhEPO itself, leading to rhEPO resistance or maladaptive hypertrophy. Identifying such potential molecular mechanisms could enable the development of better therapeutic strategies, as well as the efficient use of EPO. In this study we test this hypothesis on isoproterenol-induced cardiac remodelling with emphasis on hypertrophy.

2. Materials and methods

2.1. Culture medium and chemicals

Dulbecco's modified Eagle's medium (DMEM) containing F12 (1:1 DMEM/F12), fetal bovine serum (FBS), penicillin, streptomycin and Trypsin–EDTA were purchased from Gibco (Invitrogen, Carlsbad, CA). Isoproterenol, hematoxylin, eosin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO) and ponceau S solution were purchased from Sigma–Aldrich (St. Louis, MO). rhEPO (EPREX solution 10000 U/ml) was from Janssen-Cilag, Sydney, Australia.

2.2. Antibodies

Antibody for transforming growth factor beta (TGF-β; sc-146) was purchased from Santa Cruz Biotechnology (CA, USA). Antibody for fibronectin (A0245) was from Dako (Dako Australia, VIC, Australia) and alpha smooth muscle actin (α-SMA; A2547) was from Sigma–Aldrich (St. Louis, MO, USA). Secondary antibodies were from Molecular Probes (Life Technologies, Carlsbad, CA, USA).

2.3. Cell lines and culture

Rat myocardial cell line H9c2 was obtained from American Type Culture Collection (ATCC). The cells were cultured in DMEM/F12 containing 10% fetal bovine serum (FBS), penicillin (50 U/ml) and streptomycin (50 mg/ml) in a humidified atmosphere of 95% air and 5% CO_2 at 37 °C.

2.4. Measurement of cell surface area as a marker of hypertrophy

Changes in surface area of cells, as a marker of hypertrophy, were analysed using a modification of a previous report [14]. In brief, the cells were seeded on glass cover slips in 24-well plates at a density of 4×10^4 cells/ml. 24 h later, the cells were incubated in culture medium containing 1% FBS with or without isoproterenol (ISO; 10 μM) and rhEPO (50, 100 or 200 U/ml). The compounds were prepared fresh in culture medium. 48 h after the treatment, the cells were washed in PBS and fixed for 20 min at room temperature in 4% formaldehyde. The cells were washed and permeabilized with 0.1% Triton X-100 for 5 min. After washing the cells in PBS, the cells were stained with hematoxylin and eosin (H&E), dehydrated in ethanol, cleared in xylene and mounted on glass slides with Depex mounting medium. The cells were viewed under Nikon Eclipse 50i microscope (Nikon Instruments Inc., NY, USA) at ×200 magnification, and four random fields from each slide were photographed. The surface areas of cells from each field were determined using NIS-Elements software version Br.

2.5. Cell viability assay

The cells (5×10^3 cells/well/100 μl) were seeded in 96-well plates. 24 h later, the cells were incubated in culture medium containing 1% FBS with or without isoproterenol (ISO; 10 μM) and rhEPO (50 U/ml) and incubated in a humidified atmosphere of 95% air and 5% CO_2 at 37 °C. 48 h after the treatment, the culture medium was removed and 100 μl of fresh culture medium (without ISO or rhEPO) containing MTT (0.5 mg/ml) was added to each well and incubated in a humidified atmosphere of 95% air and 5% CO_2 at 37 °C for 90 min. The medium was removed and 100 μl of dimethyl sulfoxide (DMSO) were added to each well to dissolve the purple formazan crystals. The absorbance was read at 570 nm with a background correction of 690 nm in a Multiscan Go Microplate Reader (Thermo Scientific, Waltham, MA, USA). The percentage of cell viability was calculated relative to the control wells, which were designated as 100%.

2.6. Western blotting

Cells were grown to approximately 80% confluence in 100 mm petri dishes and treated with ISO (10 μM), EPO (50 U/ml) or both. 48 h after treatment, the culture medium was removed and the cells were washed twice in ice-cold PBS. Whole cell lysates were prepared by lysing the cells in radio-immuno precipitation assay (RIPA) buffer (1× PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS). The lysates were centrifuged at 13,000 rpm for 15 min at 4 °C. The supernatant was collected and the protein content measured using bicinchoninic acid (BCA) protein assay reagent (Pierce, Rockford, IL, USA). The lysates were aliquoted and stored at −80 °C until further use. The proteins (50 μg) were resolved in 10% Tris–HCl gel and electro-transferred into polyvinylidene fluoride membranes (Millipore Corporation, MA, USA). Equal loading of proteins was confirmed by staining the membrane with Ponceau S solution. Standard Western blotting procedures were followed, and the signals were detected by Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). The differences in intensities of the signals were analyzed by ImageJ software (National Institutes of Health, Bethesda, MD).

2.7. Data analyses

The results are expressed as mean ± standard error (SE) of mean. Comparisons between groups were performed by analysis of variance (ANOVA) with Tukey's post hoc test or Student's *t*-test, where appropriate. Analyses were performed using Graphpad Instat software (San Diego, CA, USA). $p < 0.05$ was considered significant.

3. Results

3.1. EPO reversed isoproterenol-induced hypertrophy of cardiomyocytes

Treatment of cardiomyocytes with ISO (10 μM) induced a significant increase in hypertrophy as evidenced by increases in the surface areas of the whole cells (Fig. 1 A) and the nuclei at 48 h (Fig. 1B). A representative H&E stained cells from each group is shown in Fig. 1 C. Co-treatment with EPO (50, 100 and 200 U/ml)